Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estriol) may have a role in controlling vaginal atrophy in selected and informed breast cancer women.
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy / Luciano, Mariani; Angiolo, Gadducci; Enrico, Vizza; Tomao, Silverio; Patrizia, Vici. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - STAMPA. - 29:1(2013), pp. 25-29. [10.3109/09513590.2012.705389]
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy
TOMAO, SILVERIO;
2013
Abstract
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estriol) may have a role in controlling vaginal atrophy in selected and informed breast cancer women.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
